Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.33 |
| ▸ | FAAH | O00519 | 10/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20898323 | 1.00 | KDM4E (0.40) | KDM4EALDH1A1AKR1C3FAAHBRD4 | |
| SCHEMBL20907339 | 0.94 | AKR1C3 (0.43) | KDM4EALDH1A1AKR1C3LMNA | |
| SCHEMBL22555794 | 0.94 | AKR1C3 (0.43) | KDM4EALDH1A1AKR1C3LMNA | |
| SCHEMBL22567609 | 0.94 | AKR1C3 (0.43) | KDM4EALDH1A1AKR1C3LMNA | |
| SCHEMBL22555806 | 0.91 | AKR1C3 (0.33) | KDM4EALDH1A1AKR1C3MEN1KMT2A | |
| SCHEMBL22567476 | 0.90 | AKR1C3 (0.35) | ALDH1A1AKR1C3F2R | |
| SCHEMBL22567671 | 0.90 | AKR1C3 (0.35) | KDM4EALDH1A1AKR1C3MEN1KMT2A | |
| SCHEMBL22555745 | 0.90 | KDM4E (0.44) | KDM4EALDH1A1FAAHBRD4MEN1 | |
| SCHEMBL22567383 | 0.90 | F2R (0.39) | KDM4EALDH1A1AKR1C3FAAHF2R | |
| SCHEMBL22555823 | 0.90 | KDM4E (0.44) | KDM4EALDH1A1FAAHBRD4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325915-B2 | Lysyl oxidase inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-05-10 | — | — | US | disclosed |
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-22 | — | — | US | disclosed |
| WO-2019073251-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | LOXL1, LOXL2, LOXL3 | KDM4E 974/4885ALDH1A1 1199/4885AKR1C3 985/4885 |
| US-11325915-B2 | Lysyl oxidase inhibitors | LOXL1, LOXL2, LOXL3 | KDM4E 974/4885ALDH1A1 1199/4885AKR1C3 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.